I'm guessing a lot of people saw this already, but I'll post it anyway. It does not look like a silver bullet, but I guess it's better than nothing.
FDA Authorizes [on an emergency basis] Monoclonal Antibody for Treatment of COVID-19
>>>While the safety and effectiveness of this investigational therapy continues to be evaluated, bamlanivimab was shown in clinical trials to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. . . . the most important evidence that bamlanivimab may be effective came from the predefined secondary endpoint of COVID-19-related hospitalizations or emergency room visits within 28 days after treatment. For patients at high risk for disease progression, hospitalizations and emergency room visits occurred in 3% of bamlanivimab-treated patients on average compared to 10% in placebo-treated patients. The effects on viral load and on reduction in hospitalizations and ER visits, and on safety, were similar in patients receiving any of the three bamlanivimab doses.<<<
Today, the FDA issued an EUA for an investigational monoclonal antibody therapy for treatment of mild-to-moderate COVID-19 in adult and pediatric patients.
www.fda.gov